Active Ingredient History
Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma. Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Asthma (approved 2021)
Airway Management (Phase 2)
Airway Remodeling (Phase 3)
Allergy and Immunology (Phase 1/Phase 2)
Asthma (Phase 4)
Bronchial Diseases (Phase 2)
Bronchitis (Phase 2)
Chronic Urticaria (Phase 2)
Dermatitis, Atopic (Phase 2)
Eosinophilic Esophagitis (Phase 3)
Healthy Volunteers (Phase 1)
Hypersensitivity (Phase 2)
Hypersensitivity, Immediate (Phase 2)
Immune System Diseases (Phase 2)
Lung Diseases (Phase 2)
Lung Diseases, Obstructive (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Respiratory Hypersensitivity (Phase 2)
Respiratory Tract Diseases (Phase 2)
Sinusitis (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
